Publications by authors named "Majed M Khraishi"
Article Synopsis
- The COMPLETE-PsA study evaluated the effectiveness of adalimumab (ADA) compared to nonbiologic disease-modifying antirheumatic drugs (nbDMARDs) in treating biologic-naïve Canadian adults with active psoriatic arthritis who had inadequate response to previous nbDMARD treatment.
- Conducted from 2012 to 2017, the study involved collecting data on various clinical measures and patient-reported outcomes, including disease activity scores and quality of life assessments.
- Results showed that ADA-treated patients had significantly better disease activity scores and health outcomes at 3 and 12 months, with quicker achievement of treatment milestones and lower rates of dactylitis compared to
Article Synopsis
- The objective was to create initial treat-to-target recommendations for managing psoriasis and psoriatic arthritis in Canada.
- A task force of experts conducted surveys and literature reviews to understand current practices and outcomes in treating these conditions.
- They formulated 5 key principles and 8 preliminary recommendations aimed at enhancing treatment, but emphasize the need for real-world validation to confirm their effectiveness over time.
Article Synopsis
- The Canadian Vasculitis research network (CanVasc) consists of a diverse group of physicians and researchers focused on vasculitis.
- One of their main goals is to create guidelines for diagnosing and managing ANCA-associated vasculitides in Canada.
- This summary includes 19 recommendations and 17 statements that cover general diagnosis and management of AAV, based on international guidelines and expert consensus tailored to the Canadian healthcare environment.
Objective: The Canadian Vasculitis research network (CanVasc) is composed of physicians from different medical specialties and researchers with expertise in vasculitis. One of its aims is to develop recommendations for the diagnosis and management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) in Canada.
Methods: Diagnostic and therapeutic questions were developed based on the results of a national needs assessment survey.
Experience with subcutaneous abatacept for rheumatoid arthritis: an update for clinicians.
Ther Adv Musculoskelet Dis
October 2014
Abatacept is recommended by several expert consensus groups including the 2013 update of the EULAR recommendations for the pharmacologic management of rheumatoid arthritis (RA), as a potential choice for biologic therapy for patients with RA. Initially developed, studied, and approved as an intravenous (IV) formulation, abatacept is now also available as a subcutaneous (SC) injection. Having both options available makes abatacept a particularly versatile agent for the management of RA, greatly expanding the population of patients who could benefit from this treatment.
View Article and Find Full Text PDFBackground: General practitioners/dermatologists may be aware of musculoskeletal symptoms in patients with psoriasis but may have difficulty accurately detecting psoriatic arthritis (PsA).
Objective: We sought to evaluate 3 PsA screening questionnaires-the Psoriasis and Arthritis Screening Questionnaire (PASQ), Psoriasis Epidemiology Screening Tool (PEST), and Toronto Psoriatic Arthritis Screen (ToPAS)-based on rheumatologist assessment in patients with psoriasis.
Methods: Consecutive unselected patients with psoriasis, initially evaluated by dermatologists for plaque psoriasis, were randomized to receive 1 of 3 questionnaires.
Background: Prompt identification and treatment of psoriatic arthritis (PsA) in patients with psoriasis is critical to reducing the risk of joint damage, disability, and comorbidities.
Objective: We sought to estimate PsA prevalence in patients with plaque psoriasis in 34 dermatology centers in 7 European and North American countries.
Methods: Consecutive patients were evaluated by dermatologists for plaque psoriasis and subsequently by rheumatologists for PsA.
Objective: To quantify circulating nitric oxide (NO) levels and inducible NO synthase (iNOS) expression in peripheral blood monocyte-derived macrophages (PB-MDM) from patients with inflammatory arthritis (IA) as a measure of disease activity, and to determine if there is a correlation between expression of iNOS and protein kinase C-eta (PKC-eta).
Methods: PB-MDM were isolated from whole blood of 20 patients with IA (14 rheumatoid arthritis and 6 peripheral spondyloarthropathies). Thirteen patients with osteoarthritis (OA) and 9 healthy individuals were controls.